Tumor Biology

, Volume 36, Issue 6, pp 4479–4485 | Cite as

Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis

  • Pan Shang
  • Fanling Meng
  • Yunduo Liu
  • Xiuwei Chen
Research Article


This study aimed to explore the clinical significance of AAA+ (ATPases associated with various cellular activities) nuclear coregulator cancer-associated (ANCCA) protein expression in endometrial carcinoma (EC). Correlations of ANCCA expression with clinicopathological factors and prognosis of EC patients were analyzed. Expression of ANCCA was detected in EC from 207 patients along with corresponding normal endometrium specimens by immunohistochemistry. ANCCA immunoreactivity was overexpressed in EC cases compared with that in normal endometrium (P < 0.001). High ANCCA expression was positively correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage, histological grade, depth of myometrial invasion, lymph node metastasis, lymph vascular space involvement, and recurrence but not with age and histological type. Patients with high ANCCA expression exhibited significantly poorer overall survival (OS) and disease-free survival (DFS) than patients with low ANCCA expression (P = 0.001 and 0.002, respectively). Cox multivariate analysis showed that high ANCCA expression was an independent prognostic factor for both OS (hazard ratio (HR) = 4.954, 95 % confidence interval (CI) = 1.537–15.966; P = 0.007) and DFS of patients with EC (HR = 4.237, 95 % CI = 1.295–13.859; P = 0.017). We identified ANCCA protein expression as a novel independent poor prognostic indicator in EC.


ANCCA/ATAD2 Immunohistochemistry Endometrial carcinoma Prognosis 



We express our thanks to Dr. H-T Song for the evaluation procedures.

Conflicts of interest


Grant support

This work was supported by grants of the specialized Research Fund for the Doctoral Program of Higher Education (20122307120027), postdoctoral Science Foundation of Heilongjiang Province of China (LBH-Z11067), NSFC (81201613) and the Science Foundation of Heilongjiang Province (H201336). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA: Cancer J Clin. 2009;59(4):225–49.Google Scholar
  2. 2.
    Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Annals Oncol : Off J Eur Soc Med Oncol / ESMO. 2007;18(3):409–20.CrossRefGoogle Scholar
  3. 3.
    Bidus MA, Risinger JI, Chandramouli GV, Dainty LA, Litzi TJ, Berchuck A, et al. Prediction of lymph node metastasis in patients with endometrioid endometrial cancer using expression microarray. Clin Cancer Res : Off J Am Assoc Cancer Res. 2006;12(1):83–8.CrossRefGoogle Scholar
  4. 4.
    Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol :Off J Am Soc Clin Oncol. 2011;29(24):3278–85.CrossRefGoogle Scholar
  5. 5.
    Zou JX, Duan Z, Wang J, Sokolov A, Xu J, Chen CZ, et al. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance. Mol Cancer Res : MCR. 2014;12(4):539–49.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hsia EY, Kalashnikova EV, Revenko AS, Zou JX, Borowsky AD, Chen HW. Deregulated E2F and the AAA+ coregulator ANCCA drive proto-oncogene ACTR/AIB1 overexpression in breast cancer. Mol Cancer Res : MCR. 2010;8(2):183–93.CrossRefPubMedGoogle Scholar
  7. 7.
    Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 2010;70(22):9402–12.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 2012;22(12):2315–27.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Fouret R, Laffaire J, Hofman P, Beau-Faller M, Mazieres J, Validire P, et al. A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. Clin Cancer Res : Off JAm Assoc Cancer Res. 2012;18(20):5606–16.CrossRefGoogle Scholar
  10. 10.
    Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, et al. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 2010;29(37):5171–81.CrossRefPubMedGoogle Scholar
  11. 11.
    Wan WN, Zhang YX, Wang XM, Liu YJ, Zhang YQ, Que YH, et al. ATAD2 is highly expressed in ovarian carcinomas and indicates poor prognosis. Asian Pac J Cancer Prev : APJCP. 2014;15(6):2777–83.CrossRefPubMedGoogle Scholar
  12. 12.
    Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ, et al. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res. 2009;69(8):3339–46.CrossRefPubMedGoogle Scholar
  13. 13.
    Salhia B, Kiefer J, Ross JT, Metapally R, Martinez RA, Johnson KN, et al. Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS One. 2014;9(1):e85448.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ciro M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009;69(21):8491–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Raeder MB, Birkeland E, Trovik J, Krakstad C, Shehata S, Schumacher S, et al. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLoS One. 2013;8(2):e54873.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Wu G, Lu X, Wang Y, He H, Meng X, Xia S, et al. Epigenetic high regulation of ATAD2 regulates the Hh pathway in human hepatocellular carcinoma. Int J Oncol. 2014;45(1):351–61.PubMedGoogle Scholar
  17. 17.
    Duan Z, Zou JX, Yang P, Wang Y, Borowsky AD, Gao AC, et al. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex. Prostate. 2013;73(5):455–66.CrossRefPubMedGoogle Scholar
  18. 18.
    De Angelis PM, Svendsrud DH, Kravik KL, Stokke T. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 2006;5:20.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Gynecology, The Affiliated Tumor HospitalHarbin Medical UniversityHarbinChina

Personalised recommendations